linjc16/ctgov huggingface dataset:
HD11 for Intermediate Stages

Study Overview
=================
Brief Summary
-----------------
This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.

Conditions
-----------------
Hodgkin´s Lymphoma

Intervention / Treatment
-----------------
* Drug: Adriamycin
* Drug: Bleomycin
* Drug: Vinblastine
* Drug: DTIC
* Drug: Etoposide
* Drug: Procarbazine
* Drug: Prednisone
* Drug: Vincristine
* Radiation: radiation therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hodgkin´s lymphoma (histologically proven) CS (PS) IA, IB, IIA, with one of the risk factors a-d CS (PS) IIB only with risk factor c or d bulky mediastinal mass (> 1/3 maximum transverse thorax diameter) extranodal involvement ESR > 50 (A), > 30 (B-symptoms) 3 or more lymph node areas involved written informaed consent Exclusion Criteria: Leukocytes <3000/microl Platelets <100000/microl Hodgkin´s Disease as composite lymphoma Activity index (WHO) < grade 2

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>4x ABVD plus 30Gy IF-RT | Drug: Adriamycin<br> <br> Drug: Bleomycin<br> <br> Drug: Vinblastine<br> <br> Drug: DTIC<br> <br> Radiation: radiation therapy<br>* 20 or 30Gy IF-RT<br>|
| Experimental: C<br>4x BEACOPP baseline plus 30Gy IF-RT | Drug: Adriamycin<br> <br> Drug: Bleomycin<br> <br> Drug: Etoposide<br> <br> Drug: Procarbazine<br> <br> Drug: Prednisone<br> <br> Drug: Vincristine<br> <br> Radiation: radiation therapy<br>* 20 or 30Gy IF-RT<br>|
| Experimental: B<br>4x ABVD plus 20Gy IF-RT | Drug: Adriamycin<br> <br> Drug: Bleomycin<br> <br> Drug: Vinblastine<br> <br> Drug: DTIC<br> <br> Radiation: radiation therapy<br>* 20 or 30Gy IF-RT<br>|
| Experimental: D<br>4x BEACOPP baseline plus 20Gy IF-RT | Drug: Adriamycin<br> <br> Drug: Bleomycin<br> <br> Drug: Etoposide<br> <br> Drug: Procarbazine<br> <br> Drug: Prednisone<br> <br> Drug: Vincristine<br> <br> Radiation: radiation therapy<br>* 20 or 30Gy IF-RT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hodgkin´s lymphoma, intermediate stages
The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Overview
=================
Brief Summary
-----------------
Smoking is the most important risk factor of COPD, but only a fourth of smokers had COPD in their life. There are also healthy smokers without evidence of COPD. Investigators hypothesize that innate immunity may affect this difference between COPD patients and healthy smokers, because TLR4 is the receptor of LPS, which is the one of important substance in cigarette. Investigators will measure TLR2 and TLR4 expression in lung tissue of patients whose lung will be resected. Investigators will compare the level of expression between COPD patients and healthy smokers.

Official Title
-----------------
The Expression of TLR2 and TLR4 in the Lung of COPD Patients

Conditions
-----------------
Smoking, COPD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who will have lung resection for the therapeutic cause. Exclusion Criteria: Patients who do not agree with our study protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Big Data-based Cohort Study for Cataract Patients

Study Overview
=================
Brief Summary
-----------------
Cataract is an important cause of blindness and visual impairment worldwide. At present, the only effective treatment method is surgery. The visual function of most patients can be significantly improved after surgery, but there are still 5-20% of patients whose visual function cannot be improved after surgery. Previous studies have found that the surgical complications and postoperative visual function of cataract patients are closely related to the condition of the fundus, but the current fundus camera cannot perform clear fundus imaging of cataract patients, and the existing potential visual inspections, such as retinal visual inspection, are also inaccurate. Predict postoperative visual acuity. Therefore, there is an urgent need for a reliable postoperative effect prediction system for cataract patients to provide reference for both ophthalmologists and patients. This study intends to collect patient medical record information and traditional/ultra-wide fundus photos and other multi-modal data. Firstly, this study will use artificial intelligence technology to enhance fundus photos of cataract patients to obtain clearer fundus photos. Then this study will use both medical record information and traditional/ultra-wide fundus photographs to predict postoperative vision and visual function of cataract patients.

Official Title
-----------------
A Big Data-based Cohort Study for Cataract Patients

Conditions
-----------------
Cataract, Retina Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Candidates for cataract surgery (phacoemulsification and intraocular lens implantation) within a week. Exclusion Criteria: Unwilling or unable to receive fundus photography

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of best corrected visual acuity | Change of best corrected visual acuity from baseline to 1 week after surgery | Baseline and 1 week after surgery | 
| Accuracy for detection of retinal disorders | Accuracy for detection of retinal disorders using enhanced fundus images | 1 week after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Image enhancement, Retina disorder, Cataract, Postoperative prediction
The HF-HRV Registry

Study Overview
=================
Brief Summary
-----------------
The Registry will evaluate how HRV Monitor diagnostics change after cardiac resynchronization therapy in patients with heart failure.

Official Title
-----------------
CONTAK RENEWAL® Heart Failure Heart Rate Variability Registry

Conditions
-----------------
Arrhythmia, Heart Failure

Intervention / Treatment
-----------------
* Device: Cardiac Resynchronization Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving their first CRT-D Patients who sign and date a Patient Informed Consent prior to device implant Patients who are available and willing to attend follow-up visits at the study center in which they were enrolled Exclusion Criteria: Patients who are anticipated to receive pacing modes other than DDD or VDD (i.e., chronic atrial fibrillation patients are excluded), or patients who are anticipated to receive adaptive rate therapy Patients who are younger than 18 years of age Patients whose life expectancy is less than six-months due to other medical conditions Patients with or who are likely to receive a tricuspid or other valve prosthesis Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study Women who are pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Cardiac Resynchronization Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Continuous Registration of Bioimpedance During Hemodialysis

Study Overview
=================
Brief Summary
-----------------
This studies aims at testing continuous registration of bioimpedance during hemodialysis and comparing the measurement with extracted liquid.

Detailed Description
-----------------
The purpose is to test the sensitivity and specificity of a new electronic patch in the indication of the relative change in the fluid balance. If possible, the change in hydration level should be quantified. The test is done on patients during hemodialysis. Extracted amount of fluid is used as the primary reference to the bioimpedance measurements, but other references will also be used. The measurement is made using bioimpedance measured with four electrodes and over a large frequency spectrum. Impedance measurements are made every 20 seconds throughout the test period. The measurement is recorded in a memory (flash) on each patch. At the same time as measuring bioimpedance, the temperature in the patch is recorded. After completion of the test, the data is transferred to a computer for analysis. As a reference, extracted amount of fluid, weight change, blood samples and clinical evaluation are used.

Official Title
-----------------
Continuous Registration of Bioimpedance During Hemodialysis

Conditions
-----------------
Dialysis Related Complication, Dehydration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients for hemodialysis Exclusion Criteria: Acute in-current disease. Known adverse reaction to medical adhesive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of patch performance | Establish sensitivity and specificity of patch performance relative to extracted water, weight change and blood sample results | August - December 2019 |
The Applications of Point-of-care Ultrasound in ED Unselected, Non-critical Patients

Study Overview
=================
Brief Summary
-----------------
to investigate prevalence of agreement between sonographic and clinical diagnosis in adult patients seen in an emergency department.

Detailed Description
-----------------
Point-of-care ultrasound (POCUS) can improve patient management in the emergency department (ED). However, previous studies have focused only on selected groups of patients, such as trauma, shock, dyspnea, or critically ill patients, or patients with an already known diagnosis. Most patients seen in the ED do not match these criteria. This study aims to investigate prevalence of agreement between sonographic and clinical diagnosis in adult patients seen in an emergency department.

Official Title
-----------------
The Applications of Point-of-care Ultrasound in ED Unselected, Non-critical Patients

Conditions
-----------------
Ultrasound Therapy; Complications

Intervention / Treatment
-----------------
* Diagnostic Test: ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients in the emergency department receiving ultrasonographic examinations were enrolled. Exclusion Criteria: adult patients in the emergency department not receiving ultrasonographic examinations.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ultrasound|POCUS is applied to adult patients in an emergency department.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of agreement between the sonographic diagnosis and the clinical diagnosis | ultrasound | one month | 
| length of stay at the emergency department | length of stay | one month |
External Stressors Prior to Traumatic Knee Injury in Youth Athletes.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate different aspects of mental stress aspects and its role as a potential risk factor for traumatic knee injury in youth athletes. Approximately 300 athletes (age 16-19) 50% women) who are involved in high risk sports (soccer, handball and floorball) will be included. The athletes will record his/hers traumatic knee injury together with information about training regimes and some details on injury mechanism on a web-based form. The form also includes questions about mental stressors, such as club exchange, changed game system in addition to conflict within and outside the family, etc, prior to injury. The present study will contribute new knowledge on levels of muscle function and different aspects of mental stress factors that may be related to traumatic knee injury in young athletes.

Official Title
-----------------
External Stressors Prior to Traumatic Knee Injury in Youth Athletes.

Conditions
-----------------
Traumatic Knee Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female sport high school athletes Aged 15-19 years Participating and competing in soccer, handball, or floorball Exclusion Criteria: Traumatic knee injury prior to sport high school. -

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Athletes with traumatic knee injury<br>Youth athletes, aged 16-19, with traumatic knee injury | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants that had occurred an injury during the last year | Data on injury are collected retrospectively using a web-designed (SurveyMonkey®) registration form. | 12 months | 
| Number of participants with one ore several mental stressors related to environmental and social conditions | Mental stressors, such as club exchange, changed game system, conflict within the family, examination at school etc will be recorded using a questionnaire. | 12 months |
Use of ctDNA for Monitoring of Stage III Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

Detailed Description
-----------------
Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that originate from apoptotic or necrotic tumor cell turnover. Characteristic of the malignant process, ctDNA can be assessed in plasma and offers the potential of a sensitive and specific biomarker for prognostic information on disease-free or overall survival, and predictive information on chemotherapy resistance and probability of lack of response to treatment. This study will evaluate ctDNA as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC). We will recruit newly diagnosed stage III CRC patients, determine their tumor mutational profile, and systematically collect high volume (>10 ml), serial plasma specimens every 3 months for up to 3 years and every 6 months in years 4-5 for ctDNA and concurrent carcinoembryonic antigen (CEA) measurement. Clinical outcome and survival will be tracked. The resulting data will permit assessment of ctDNA as a prognostic marker for disease-free and overall survival and as a monitor of disease recurrence in comparison with CEA.

Official Title
-----------------
Use of ctDNA for Monitoring of Stage III Colorectal Cancer

Conditions
-----------------
Stage III Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women with CRC Stage III A, B, or C Age ≥18 years Willingness to provide blood samples for research purposes Ability to understand written informed consent document, and written informed consent provided Exclusion Criteria: Blood sampling would compromise patients overall health such as presence of severe anemia Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ctDNA assessment and relation to clinical outcome | The relationship between ctDNA and survival (both progression-free and overall) will be evaluated. Both the total load of ctDNA and the specific mutation(s) identified will be evaluated. | up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ctDNA versus CEA | ctDNA predictors of outcome will be compared to CEA | up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer
Multicenter Assessment of a Bedside-testing System (Nephrocheck™) for Acute Kidney Injury After Thoracoabdominal Aortic Surgery

Study Overview
=================
Brief Summary
-----------------
Assessment of postoperative acute kidney insufficiency according to the KDIGO classification using the Nephrocheck system. Multicentric, prospective study Open TAAA Repair in 3-4 centers in Germany and Europe

Official Title
-----------------
Multicenter Assessment of a Bedside-testing System (Nephrocheck™) for Acute Kidney Injury After Thoracoabdominal Aortic Surgery

Conditions
-----------------
Early Assessment of AKI After TAAA Repair

Intervention / Treatment
-----------------
* Other: Nephrocheck bed side testing of AKI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective open TAAA repai 18-80 years no pregnancy Exclusion Criteria: emergency treatment participation in another Trial renal replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute kidney injury after open TAAA repair | Acute kidney injury defined according to the KDIGO classification and its association with the Nephrocheck assessment results | 90 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality, major adverse events such as any complication | Any severe adverse Outcome after open TAAA repair and its association with the Nephrocheck assessment results | 90 days after surgery |
Ambulatory Blood Pressure and Prognosis

Study Overview
=================
Brief Summary
-----------------
To continue a prospective study of the ability of ambulatory blood pressure to predict cardiovascular morbidity in patients with mild hypertension.

Detailed Description
-----------------
BACKGROUND: This was a continuation of a prospective study of the ability of ambulatory blood pressure to predict cardiovascular morbidity in patients with mild hypertension, which was first started in 1978. DESIGN NARRATIVE: Predictor variables evaluated at entry to the longitudinal study included clinic and ambulatory blood pressures (including measures of pressure level and variability in different settings), left ventricular mass index (LVMI, determined by echocardiography), renin-sodium profile, and other cardiovascular risk factors (e.g., cholesterol and smoking). During follow-up, blood pressure, treatment status, BMI, and clinical course were evaluated. Outcome measures were definite cardiovascular morbid events, defined as sudden cardiac death, myocardial infarction, stroke, congestive heart failure, and coronary artery revascularization. The main hypotheses tested were that ambulatory blood pressure would give a better prediction of outcome than clinic pressure, and that patients with white coat hypertension (defined as a high clinic pressure and normal ambulatory pressure) would be at low risk relative to patients with sustained hypertension. Initial results in 729 patients initially studied between 1978 and 1985 using Cox survival analysis showed that the four most significant predictors of morbid events were daytime blood pressure variability, age, male sex, and serum cholesterol. Patients with white coat hypertension appeared to be at a level of risk intermediate between normotensives and sustained hypertensives, but the differences were not yet significant. Expansion of the cohort size to include patients evaluated initially between 1985 and 1990 provided nearly 2,000 patients altogether, which together with the longer follow-up of the initial cohort provided a sufficient number of morbid events to identify the predictive significance of the different blood pressure measures, and their interaction with other risk factors. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |